Hormones, E.g., Prolactin, Thymosin, Growth Factors, Etc. Patents (Class 530/399)
-
Publication number: 20130288963Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an anti-angiogenic effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: ApplicationFiled: January 5, 2012Publication date: October 31, 2013Applicant: ADAMED SP. Z O.O.Inventors: Jerzy Szczepan Pieczykolan, Sebastian Dominik Pawlak, Bartlomiej Maciej Zerek, Piotr Kamil Rózga
-
Publication number: 20130288960Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem.: HOOC—(CH2)x—CO—* Chem. 2: HOOC—C6H4-0-(CH2)y—CO—* Chem. 3: R2—C6H4—(CH2)z—CO—*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R2 is a group having a molar mass not higher than 150 Da; and the linker comprises Chem. 4: *—NH—(CH2)2-(0-(CH2)2)k-0-(CH2)n—CO—*. wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof.Type: ApplicationFiled: November 9, 2011Publication date: October 31, 2013Applicant: Novo Nordisk A/SInventors: Alice Ravn Madsen, Birgit Wieczorek, Jacob Kofoed, Jesper Lau, Jane Spetzler, Janos Tibor Kodra, Lars Linderoth, Patrick William Garibay, Per Sauerberg, Thomas Kruse
-
Patent number: 8568737Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: GrantFiled: August 1, 2008Date of Patent: October 29, 2013Assignees: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, Jr., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
-
Patent number: 8568736Abstract: Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: GrantFiled: March 21, 2008Date of Patent: October 29, 2013Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald T. Juppner
-
Publication number: 20130274182Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: March 28, 2013Publication date: October 17, 2013Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Jonathan David Roth
-
Publication number: 20130274185Abstract: A pharmaceutical for pseudo-exercise therapy containing an adiponectin receptor 1 agonist compound as an active ingredient and changing the physiological state of muscle to a post-exercise one without applying an exercise stress to the muscle.Type: ApplicationFiled: March 15, 2011Publication date: October 17, 2013Applicant: THE UNIVERSITY OF TOKYOInventors: Takashi Kadowaki, Toshimasa Yamauchi, Masato Iwabu, Miki Iwabu
-
Patent number: 8557768Abstract: The ?-subunit of human nerve growth factor (?NGF) is prepared in essentially pure form in commercially useful quantities using recombinant DNA technology. The nucleotide sequence and vectors encoding human ?NGF and host cells transformed with the vectors are also provided. The ?NGF which the invention provides is useful, for example, in treating nerve damage.Type: GrantFiled: April 4, 1995Date of Patent: October 15, 2013Assignee: Genentech, Inc.Inventors: Alane M. Gray, Axel Ullrich
-
Publication number: 20130266512Abstract: A Diels-Alder adduct of a trans-cyclooctene with a tetrazine is provided, wherein the adduct bears a substituent labeled with a radionuclide. A method of producing a PET or other image of an organ in an animal or human includes forming the Diels-Alder adduct in the animal or human. Trans-cyclooctenes and tetrazines suitable for preparing the adducts are provided.Type: ApplicationFiled: July 21, 2011Publication date: October 10, 2013Applicants: University of Southern California, University of DelawareInventors: Joseph M. Fox, Matthew Hassink, Melissa Blackman, Zibo Li, Peter S. Conti, Ramajeyam Selvaraj
-
Patent number: 8552158Abstract: Method for the production of IGF-I, characterized by cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and cleaving said fusion protein with IgA protease, and recovering said IGF-I. IGF-I is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: GrantFiled: August 29, 2007Date of Patent: October 8, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Stephan Fischer, Friederike Hesse, Hendrik Knoetgen, Kurt Lang, Joerg Thomas Regula, Christian Schantz, Andreas Schaubmar
-
Patent number: 8546328Abstract: The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the composition of the invention is free from tartaric acid or salts thereof and from succinic acid and salts thereof as buffering agents and does not contain amino acids as stabilizer. The composition has a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.Type: GrantFiled: August 27, 2008Date of Patent: October 1, 2013Assignee: BioGeneriX AGInventors: Walter Hinderer, Christian Scheckermann
-
Patent number: 8546086Abstract: The invention relates, inter alia, to the use of neuregulin-? as an indicator in a method for detecting a neuronal process. The invention furthermore relates to the use of neuregulins, preferably a neuregulin isoform having an isoelectric point in the range from pH 4.3 to 5.0, as a target for detecting and/or exerting an influence on neuronal processes, in particular for exerting an influence on long-term memory. Neuregulins, in particular neuregulin-? and also substances which exert an influence on the status, i.e. the expression and/or post-translational modification, of neuregulin-?, can therefore be used as agents for controlling the course of, treating and/or alleviating neuronal diseases, e.g. Alzheimer's disease.Type: GrantFiled: February 25, 2011Date of Patent: October 1, 2013Assignee: Mind-NRG SAInventor: Andre Schrattenholz
-
Publication number: 20130253170Abstract: An HA-protein conjugate in which an HA-aldehyde derivative, in which an aldehyde group is introduced to a hyaluronic acid or a salt thereof, is conjugated to the N-terminus of a protein, and a method for preparing the same are provided. The HA-protein conjugate includes a protein drug exhibiting an excellent bioconjugation efficiency and long-term medicinal effects, and has excellent protein drug activities since the hyaluronic acid is specifically conjugated to the N-terminus of the protein. Also, since liver-targeting properties of the hyaluronic acid can be freely controlled by changing an aldehyde substitution rate of the HA-aldehyde derivative, the HA-protein conjugate can be effectively used as a protein drug for treating liver diseases, and also be useful in enabling long-term medicinal effects of a protein drug required to bypass the liver. Accordingly, the HA-protein conjugate can be effectively used for a drug delivery system of proteins.Type: ApplicationFiled: December 5, 2011Publication date: September 26, 2013Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Sei Kwang Hahn, Jeong A. Yang, Seung Kyu Yoon, Won Hee Hur, Ki Tae Park, Hye Min Kim, Hyun Tae Jung
-
Publication number: 20130252884Abstract: Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described.Type: ApplicationFiled: June 6, 2011Publication date: September 26, 2013Applicant: NOVO NORDISK A/SInventors: Patrick William Garibay, Helle Woeldike, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Tina Moeller Tagmose
-
Publication number: 20130251637Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.Type: ApplicationFiled: December 20, 2011Publication date: September 26, 2013Applicants: DYOMICS GMBH, PIERCE BIOTECHNOLOGY, INC.Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa Dworecki, Frank G. Lehmann
-
Publication number: 20130244938Abstract: Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided.Type: ApplicationFiled: January 31, 2013Publication date: September 19, 2013Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventor: The Board of Trustees of the Leland Stanford Junior University
-
Patent number: 8535912Abstract: The present invention is directed to novel chimeric fibroblast growth factor (FGF) polypeptides, novel DNA encoding chimeric FGF polypeptides, and to the recombinant production of chimeric FGF polypeptides, and to methods, compositions and assays utilizing chimeric FGF polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for producing pharmaceutically active compositions including chimeric FGF polypeptides, the compositions having therapeutic and pharmacologic properties including those associated with the treatment of metabolic-related disorders and other conditions.Type: GrantFiled: October 15, 2010Date of Patent: September 17, 2013Assignee: Genentech, Inc.Inventor: Junichiro Sonoda
-
Publication number: 20130236959Abstract: Thermostable FGF-2 proteins having enhanced ability to support human pluripotent stem cell cultures are provided. Also provided are methods and compositions utilizing thermostable FGF-2 proteins.Type: ApplicationFiled: December 17, 2012Publication date: September 12, 2013Inventors: Guokai Chen, James A. Thomson, Zhonggang Hou
-
Patent number: 8530419Abstract: A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.Type: GrantFiled: November 27, 2012Date of Patent: September 10, 2013Assignee: Thorn BioScience LLCInventor: James W. Lauderdale
-
Patent number: 8530174Abstract: The present invention relates to the identification of polynucleotides and polypeptides involved in insulin and adiponectin signaling and regulation of glucose production. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of glucose production and the monitoring and treatment of metabolic disorders such as diabetes.Type: GrantFiled: June 4, 2010Date of Patent: September 10, 2013Assignee: The University of North Carolina at Chapel HillInventors: Terry P. Combs, James A. Swenberg
-
Patent number: 8530417Abstract: The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and use thereof.Type: GrantFiled: December 29, 2007Date of Patent: September 10, 2013Assignee: Biosteed Gene Expression Tech Co. Ltd.Inventors: Shiyuan Wang, Jianhua Zheng, Li Sun, Huili Cai, Meihua Yang, Yan He, Ping Chen, Hongyuan Deng, Liping Zhong, Shuying Huang
-
Patent number: 8530620Abstract: The present invention relates to reagents and methods for [18F]-fluorination of biomolecules, particularly of peptides. The resultant 18F-labelled compounds are useful as radiopharmaceuticals, specifically for use in Positron Emission Tomography (PET).Type: GrantFiled: March 22, 2010Date of Patent: September 10, 2013Assignee: GE Healthcare LimitedInventors: Dag Erlend Olberg, Joseph Maduabuchi Arukwe
-
Publication number: 20130231283Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.Type: ApplicationFiled: February 1, 2013Publication date: September 5, 2013Applicant: DeveloGen AktiengesellschaftInventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
-
Publication number: 20130231277Abstract: The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-?Klotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-?Klotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: March 4, 2013Publication date: September 5, 2013Applicant: NEW YORK UNIVERSITYInventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20130225490Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: ApplicationFiled: May 6, 2013Publication date: August 29, 2013Applicant: IMMUNEX CORPORATIONInventors: John Ernest Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
-
Publication number: 20130224835Abstract: The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I) with a compound of formula (II): or, a compound of formula (III) with a compound of formula (IV) in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.Type: ApplicationFiled: April 2, 2013Publication date: August 29, 2013Applicant: HAMMERSMITH IMANET LIMITEDInventor: HAMMERSMITH IMANET LIMITED
-
Publication number: 20130225493Abstract: The present invention relates to fibroblast growth factor 18 (FGF-18) variants having various truncations beyond the signal peptide domain of the N-terminus, which activate FGFR3 with increased specificity. The invention further relates to polynucleotides encoding the variants, pharmaceutical compositions comprising same and methods for use thereof in treating cartilage and skeletal disorders.Type: ApplicationFiled: March 21, 2013Publication date: August 29, 2013Inventors: Avner Yayon, Eran Rom, Roy Sirkis, Dalit Strauss-Ayali
-
Patent number: 8518411Abstract: The invention provides modified TGF-? family proteins having altered biological or biochemical properties, and methods for making them. Specific modified protein constructs include TGF-? family member proteins that have N-terminal truncations, “latent” proteins, fusion proteins and heterodimers.Type: GrantFiled: March 7, 2007Date of Patent: August 27, 2013Assignee: Stryker CorporationInventors: Hermann Oppermann, Mei-Sheng Tai, John McCartney
-
Patent number: 8518878Abstract: It is to provide a method for treating skin aging, or a method for treating skin scar that can exert a sufficient effect. A composition for treating skin aging comprising bFGF for treating aging of the skin that is administered intradermally or subcutaneously, or a composition for treating skin scar comprising bFGF for treating scar of skin that is administered intradermally or subcutaneously is utilized. Preferred examples of aging of skin include skin wrinkle, pigmented spot, sagging skin, rough skin, skin thinning, decrease of skin viscoelasticity, etc., and preferred examples of scar include keloid, hypertrophic scar, scar contracture, etc.Type: GrantFiled: September 15, 2011Date of Patent: August 27, 2013Assignee: Labo Juversa Co., Ltd.Inventor: Ichiro Ono
-
Patent number: 8518877Abstract: The present invention relates to a composition comprising Insulin Growth Factor I (IGF-I) or an analog thereof in combination with Insulin Growth Factor Binding Protein (IGFBP) or an analog thereof, such combination having a molar ratio of IGF-I to IGFBP being lower than equimolar, preferably in the range from 1:20 to 1:3.33, for use in the treatment of a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth, as well as a method for treating a patient suffering from complications of preterm birth, very preterm birth and/or extremely preterm birth.Type: GrantFiled: April 18, 2008Date of Patent: August 27, 2013Assignee: Premacure ABInventors: Ann Hellstrom, Chatarina Lofqvist, Lois Smith
-
Publication number: 20130216588Abstract: An insulin-gold nanocluster, a pharmaceutical composition for treating diabetes comprising the insulin-gold nanocluster, and a method for detecting adipose cells in a tissue by using the insulin-gold nanocluster are provided. Herein, the insulin-gold nanocluster of the present invention comprises: a gold nanocluster, and insulin connecting to the gold nanocluster, wherein the insulin-gold nanocluster emits red fluorescence at maximized wavelength of 670 nm.Type: ApplicationFiled: February 17, 2012Publication date: August 22, 2013Inventors: Pi-Tai CHOU, Chien-Liang Liu, Yun-Chen Chien
-
Publication number: 20130217867Abstract: A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.Type: ApplicationFiled: March 26, 2013Publication date: August 22, 2013Applicant: Genentech, Inc.Inventor: Genentech, Inc.
-
Publication number: 20130217623Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.Type: ApplicationFiled: March 18, 2013Publication date: August 22, 2013Applicant: HOFFMANN-LA ROCHE INC.Inventor: HOFFMANN-LA ROCHE INC.
-
Publication number: 20130216479Abstract: Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous adducts such as, the corresponding oxime derivatives is provided. Methods of making and using the adducts in radio-labelling, molecular imaging applications, and treatment of disorders such as cancer, Crohn's disease, arthritis, atherothrombosis and plaque rupture are also provided.Type: ApplicationFiled: April 1, 2013Publication date: August 22, 2013Inventors: Alexander Krantz, Peng Yu
-
Publication number: 20130216475Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.Type: ApplicationFiled: April 2, 2013Publication date: August 22, 2013Applicant: Genentech, Inc.Inventor: Genentech, Inc.
-
Publication number: 20130217621Abstract: A supramolecular insulin assembly and supramolecular exendin-4 assembly, which is useful as a protein therapeutic agent for the treatment of metabolic disorders particularly diabetes. The supramolecular assemblies disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising the supramolecular assembly.Type: ApplicationFiled: March 18, 2013Publication date: August 22, 2013Inventors: Avadhesha Surolia, Sarika Gupta, Mahendra Pal Singh, Tandrika Chattopadhyay
-
Publication number: 20130217630Abstract: The invention relates to PTH variants and uses thereof in the detection, diagnosis, and treatment of various disease states.Type: ApplicationFiled: October 26, 2011Publication date: August 22, 2013Applicant: ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona, acting for an on behalf of ArizoInventors: Randall W. Nelson, Paul Oran
-
Patent number: 8513192Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.Type: GrantFiled: January 22, 2010Date of Patent: August 20, 2013Assignee: Novo Nordisk A/SInventors: Ole Hvilsted Olsen, Jens Breinholt, Christine Bruun Schiødt, Helle Demuth, Leif Nørskov-Lauritsen, Peter Thygesen
-
Patent number: 8513191Abstract: The objects of the present invention are to provide a therapeutic agent and a therapeutic method for periodontal diseases and pulpal diseases, a transplant for periodontal tissue regeneration, and a method for regenerating the periodontal tissue. According to the present invention, there are provided therapeutic agents for periodontal diseases and pulpal diseases which comprise neurotrophic factors as an active ingredient.Type: GrantFiled: March 5, 2012Date of Patent: August 20, 2013Assignees: Two Cells Co. Ltd.Inventors: Hidemi Kurihara, Hiroyuki Kawaguchi, Katsuhiro Takeda, Hideki Shiba, Noriyoshi Mizuno, Hiroshi Yoshino, Naohiko Hasegawa, Hiroaki Shinohara
-
Publication number: 20130209994Abstract: The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins, nucleic acids and cellular organelles. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified to provide beneficial properties.Type: ApplicationFiled: January 3, 2013Publication date: August 15, 2013Applicant: ENZO LIFE SCIENCES, INC.Inventor: ENZO LIFE SCIENCES, INC.
-
Publication number: 20130211054Abstract: The present invention provides a method for purifying a large amount of human granulocyte-colony stimulating factors (hG-CSFs) from a recombinant E. coli with high yield and purity. According to the method of the present invention, human granulocyte-colony stimulating factor, identical to the native form expressed in the human body, can be easily purified with high yield and purity without an additional activation process. In particular, according to the purification method of the present invention, hG-CSF variants expressed in E. coli are efficiently removed to obtain physiologically active hG-CSFs with high purity.Type: ApplicationFiled: October 26, 2011Publication date: August 15, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Sung Chul Choi, Jin Ki Kim, Young Hak Oh, Jong Soo Lee
-
Publication number: 20130203060Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: ApplicationFiled: April 1, 2013Publication date: August 8, 2013Applicant: Merck Sharp & Dohme Corp.Inventor: Merck Sharp & Dohme Corp.
-
Publication number: 20130202552Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membrane signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.Type: ApplicationFiled: February 11, 2013Publication date: August 8, 2013Applicant: APOTECH RESEARCH AND DEVELOPMENT LIMITEDInventor: APOTECH RESEARCH AND DEVELOPMENT LIMITED
-
Publication number: 20130203661Abstract: The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.Type: ApplicationFiled: March 28, 2013Publication date: August 8, 2013Applicants: ASTRAZENECA PHARMACEUTICALS LP, Amylin Pharmaceuticals, LLCInventors: Amylin Pharmaceuticals, LLC, ASTRAZENECA PHARMACEUTICALS LP
-
Publication number: 20130196909Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relate to methods of making and using the truncated growth factors.Type: ApplicationFiled: March 24, 2011Publication date: August 1, 2013Applicant: LIFENET HEALTHInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
-
Publication number: 20130195764Abstract: The invention provides compositions and methods that provide a solution to the difficulties in diagnosing ischemia, e.g., identifying specific affected anatomical areas, and treating ischemic tissue so as to minimize damage and promote healing of damaged tissue in a subject such as a human or other animal.Type: ApplicationFiled: April 20, 2011Publication date: August 1, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Jaeyun Kim, Lan Cao, David J. Mooney
-
Publication number: 20130195807Abstract: Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists.Type: ApplicationFiled: June 3, 2011Publication date: August 1, 2013Inventors: Andrew V. Schally, Barbara Ludwig, Stefan Bornstein, Norman L. Block
-
Publication number: 20130196911Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.Type: ApplicationFiled: March 24, 2011Publication date: August 1, 2013Applicants: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Steven M. Jay, Linda G. Griffith, Richard T. Lee
-
Publication number: 20130196910Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.Type: ApplicationFiled: March 24, 2011Publication date: August 1, 2013Applicant: LIFENET HEALTHInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
-
Publication number: 20130190478Abstract: The current invention reports a method for the purification of a non-glycosylated, heterologous polypeptide, which has been recombinantly produced in a prokaryotic cell, wherein the method comprises three chromatography steps of which the first chromatography step selected from i) hydrophobic charge induction chromatography, or ii) hydrophobic interaction chromatography, or iii) affinity chromatography, or iv) ion exchange chromatography, the second chromatography step is selected from i) anion exchange chromatography, or ii) cation exchange chromatography, or iii) hydroxylapatite chromatography, or iv) hydrophobic interaction chromatography, and the a third chromatography step is selected from i) hydrophobic charge induction chromatography, or ii) anion exchange chromatography, or iii) cation exchange chromatography, or iv) hydrophobic interaction chromatography, whereby the first chromatography step is an affinity chromatography in case of polypeptides capable of interacting with metal ligands, the second cType: ApplicationFiled: September 21, 2012Publication date: July 25, 2013Inventor: Hoffmann-La Roche Inc.
-
Publication number: 20130190232Abstract: Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD).Type: ApplicationFiled: July 18, 2011Publication date: July 25, 2013Applicant: NOVO NORDISK A/SInventors: Tina Moeller Tagmose, Patrick William Garibay, Xujia Zhang, Henning Thoegersen, Peter Kresten Nielsen, Birgitte Andersen, Jishu Wang, Kristian Sass Bak-Jensen, Helle Fabricius Woeldike